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Introduction 
 
PLATFORMS FOR MICROFLUIDICS 
Pioneering work from H. Michael Widmer's group in the early 90's was aimed at the 
miniaturization of analytical systems in order to establish fast and sensitive methods (1). 
The first application reported was the implementation of capillary electrophoresis (CE) 
separations on planar glass chips (2). CE in its conventional form is performed in a one-
dimensional fused silica capillary, and requires the introduction of a large amount of 
sample into the capillary (c.a. 1% of the total length, 1-50 nL) in order to achieve 
reproducible separations. The use of two-dimensional microfluidic channel networks 
enables the handling of much smaller sample volumes. The time required for the separation 
of individual species from a sample decreases with sample volume. With microfluidic 
systems, it is possible to achieve the delivery of pL sample volumes, and therefore, CE-on-
chip can be performed considerably faster than regular CE. Optimization of channel 
geometry and electric fields in a chip enabled sub-millisecond separation time (3). As 
foreseen by Widmer and Manz, the application of bi-dimensional integrated systems goes 
far beyond the scope of fast CE separations. The design of interconnected channels and 
reaction chambers of various sizes could ultimately yield a chip that can process a sample 
through all the steps usually carried out in a laboratory. This concept is known as the 
Minaturized Total Analysis System (µTAS) or Lab-on-a-chip. Numerous sample-handling 
steps have been individually realized on microfluidic platforms, such as serial/parallel 
dilutions (4), pneumatic mixing (5), organic synthesis (6), PCR (7) and cell handling (8). 
Recent developments are well covered in reviews (9, 10). The coupling of sample-handling 
steps on a single chip will provide µTAS chips with fully automated preparation and fast 
analysis of samples. The use of miniaturized systems will also require less power and 
smaller amounts of reagent to perform the assays. Since most of the analytical steps of the 
assay take place on the chip, the instruments that run the µTAS chip will be small, highly 
automated and possibly portable. 
Several techniques developed for the microelectronics industry have been directly used for 
the fabrication of microfluidic platforms. For instance, photolithographic processes based 
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on photosensitive polymers give access to patterned surfaces. Selective etching of the 
patterned materials enables micromachining of the surface to obtain microchannels. 
Moreover, selective metal deposition can be used for the fabrication of microelectrodes for 
the purpose of electrochemical detection or dielectrophoresis. The first materials 
investigated were Pyrex (2) and quartz (11) (SiO2) because they were chemically inert, 
transparent, and therefore suitable for fluorescence measurements. Another widely used 
material is silicon, which can be easily micromachined using the numerous techniques 
available from the microelectronics industry. However, silicon is not transparent, is 
unstable in the presence of alkaline solutions, and cannot withstand the high voltages 
required to move liquids electroosmotically (12). Therefore, silicon has been found more 
attractive as a substrate for microchannel replication in polymers (see later) than as a 
material for microchip fabrication. In these materials, three different channel cross sections 
are available (see Figure 1). Two etching methods taking place in aqueous media are 
available. KOH-wet etching on silicon provides trapezoidal profiles, whereas HF-wet 
etching of SiO2 gives rectangular profiles, with rounded sidewalls. These techniques are 
well suited for low height/width aspect ratios. In a dry environment, rectangular structures 
of high aspect ratio can be obtained by deep reactive ion etching (DRIE).  
(a) (d)(c)(b)
 
Figure 1: Several types etching profile are obtained by varying the etching conditions. 
(a) KOH-wet etching of silicon, (b) HF-wet etching in SiO2 substrates and (c, d) 
DRIE. 
Due to the high costs of microfabrication technology and the starting material described 
above, polymeric materials have been used for the mass production of batches of structures 
at low costs. However, polymeric microchannels are generally more hydrophobic and 
don’t have electrical charges on their surface, resulting in stronger sample adsorption to 
channel walls and lower electroosmotic flows (EOF, see later the discussion about EOF) 
(17). Poly(dimethylsiloxane) (PDMS) has been reported as an attractive material for 
microchannel replication (13-15). Structured PDMS surfaces are obtained quickly and are 
transparent over the entire visible spectrum of light. Moreover, PDMS replicates can be 
sealed to virtually any flat material to obtain channels. The use of other polymers such as 
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acrylic copolymer  (16-17), poly(methylmethacrylate) (PMMA) (18), polystyrene (PS) 
(17), copolyester (17) and poly(ethyleneterephtalate) glycol, (PETG) (19) have also been 
reported. These microfluidic platforms are obtained by replication of a master pattern into 
polymeric materials, using casting, hot embossing or injection molding techniques. 
Fabrication of the original master pattern requires a high level of precision and is often 
carried out in a clean room environment by silicon etching, thick photoresist patterning 
(with e.g. SU-8) or growth of galvanic structures. Casting is the quickest method to set up 
and is appropriate for the fabrication of small series of prototypes. Hot embossing enables 
the fabrication of hundreds or thousands of prototypes, but requires more complicated 
instrumentation for the tight control of temperature and applied pressure during the 
embossing step. Injection molding (20) is carried out only in an industrial environment for 
the mass production of inexpensive replicated chips, and is certainly not appropriate for 
prototyping. 
MASS TRANSPORT TECHNIQUES IN MICROCHANNELS 
Glass materials are made of SiO2, with SiOH groups at the surface. These groups behave 
like weak acids and therefore remain protonated (SiOH form) in acidic media, but 
dissociate when pH is gradually increased to reach alkaline conditions. The pKa value of 
SiOH groups is approximately 6 (21). Thus in neutral or alkaline aqueous conditions, the 
surface of channels made of SiO2 material (fused silica, quartz, Pyrex or glass) is covered 
by fixed, negatively charged SiO- groups that are counterbalanced by a layer of cations 
(often Na+). Upon application of an electric field along the channel, all electric charges will 
experience a dragging force towards the electrode of opposite sign. The layer of positively 
charged counter ions will move towards the cathode, dragging solvent with them. 
However, the negatively charged SiO- groups are bound to the surface by covalent bonds, 
and therefore cannot be displaced in the electric field.  
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Figure 2: Schematic view of electroosmotic flow generation. (a) In a neutral or 
alkaline pH, the negatively charged SiO- groups are electrically counterbalanced by a 
diffuse layer of cations. (b) Upon application of a high electric field, the motion of the 
cations is transferred to the rest of the liquid. 
Thus, a net mass flow towards the cathode is observed in a thin annular region close to the 
surface. This motion is transferred to the rest of the liquid contained in the capillary by 
viscous forces and is refered to as electroosmosis (see Figure 2). The transfer process to the 
fluid located at the channel center takes less than 1 ms. This phenomenon is strongly 
dependent on the presence of electrically charged groups at the surface of the material, and 
the more groups, the stronger the electroosmosis. A physical unit known as zeta potential 
(ζ), describes the difference in potential close to the surface. The solution present at the 
interface is capable of changing ζ, either by increasing the number of electric charges at 
the material surface (e.g. using a more alkaline buffer) or by changing the distance between 
the wall and the plane of shear, where ζ is defined (e.g. varying the buffer ionic strength). 
The viscosity-induced motion transfer mechanism from the surface to the bulk liquid is 
also influenced by variation in temperature (22). The resulting electroosmotic mass 
transport velocity (vEOF) is described by the equation 1:  
 Ev EOFEOF ⋅= µ         with        η
ζεµ ⋅=EOF             [1] 
Where µEOF is the electroosmotic mobility, ε is the dielectric constant, ζ is the zeta 
potential and η is the solution viscosity. Unfortunately, electroosmosis cannot be used in 
electrically conductive substrates, due to its requirements for high voltages. Therefore, 
silicon microstructures, though easily processed, cannot withstand the voltages required for 
electroosmosis (12), whereas SiO2 channels are fully suitable.  
Mass transport in the microfluidic network is also possible using pressure-driven flows 
(either positive or negative pressure). In theory, pressure-driven flows do not downscale 
well, since smaller channel dimensions require a higher pressure drop in order to maintain 
the flow velocity. However, they are easily set up and are suitable for mass transport in 
channels made of conductive material, such as silicon. The major difference between 
electroosmotic and pressure-driven flow lies in the velocity profile in the channel. In case 
of pressure-driven flows, the flow velocity is zero at the channel wall, and gradually 
increases towards the center of the channel, according to a parabolic profile. Therefore, a 
section of fluid introduced into a channel will be distorted upon transport, as the fluid 
located in the central part of the channel moves faster than that close to the walls (see 
Figure 3a).  
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However, electroosmotic transport is characterized by a uniform distribution of flow 
velocities over the channel (see Figure 3b), except very close to the channel walls. For 
liquid chromatography applications, the separations appear more efficient using 
electroosmosis than pressure-driven flows, due to lower dispersion by the flow profile. 
When manipulating flows in complex microchannel networks, electroosmotic pumping is a 
convenient tool for tuning liquid flow in individual channels, by varying the applied 
voltages at each channel end. However, upon application of a high electric field in a 
microchannel, electrophoresis takes place as well. Therefore the apparent transport velocity 
is the sum of the electroosmotic and electrophoretic velocities. In channels made of glass 
(SiO2 in general), and under alkaline conditions, electroosmosis is strong and overrules 
electrophoresis, resulting in a net flow of most analytes in the direction of the cathode. 
However, the cations will be displaced faster than the electroosmotic flow, whereas the 
anions will be retarded. Electroosmotic flow velocity is characterized by the parameter 
µEOF, which is specific for each material and liquid. The electroosmotic mobility of a 
material is commonly measured using either a current monitoring method (23) or by 
recording the migration time of a neutral marker. The use of an electrically neutral 
molecule is important, in order to eliminate the electrophoretic contribution to the 
transport. 
FLUORESCENCE 
Most molecules have the ability to absorb photons at a given wavelength, and during this 
process the photon transfers its energy to the molecule. This excess energy is normally 
dissipated in the form of vibration, rotation or translation. However, some molecules have 
the ability to re-emit part of this energy as longer wavelength photons, by means of 
fluorescence. In more detail, upon absorption of a photon, an electron gains enough energy 
to move from a ground state energy towards an excited state. The electron will then lose 
part of its energy by internal conversion to reach the lowest energy mode of the excited 
state. Finally, the electron returns to the ground state energy, and the remaining energy is 
released in the form of a photon. Due to the loss of energy during the internal conversion in 
the excited state, the total energy of the emitted photon is lower than that of the excitation 
photon. The resulting difference between the excitation and emission wavelength is called 
the Stokes' shift. The presence of a small shift in wavelength enables the detection of a 
small number of emitted photons in presence of large excess of excitation photons. A 
 molecule can repeat a fluorescence emission cycle numerous times (e.g. fluorescein, 
30'000 cycles), before the excited state alters the molecular structure. Therefore, upon long 
exposure time or high light intensities, the fluorescence signal decreases proportionally to 
the excitation light intensity, a phenomenon known as photobleaching. 
Many chemical structures are known to be fluorescent, one of the most common being 
fluorescein (see Figure 4a). The spectral characteristics of the fluorescing base structures 
are sensitive to their chemical environment. One example is fluorescein, which is excited 
at 488 nm. Addition of four electron-rich bromine atoms and a sulfonic group on the π-
system (see Figure 4b) modifies the electronic environment and shifts the excitation to 532 
nm. Cyanine dyes are composed of heterocyclic ends linked by a variable spacer arm. The 
length of the spacer determines the spectral characteristics of the dye. For instance, the 5C-
atom long spacer of Cy5 (Figure 4c) makes for an excitation wavelength of 650 nm, 
whereas a 3-atom long spacer shifts the excitation down to 532 nm (Cy3).  
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observation is also possible, using a series of dyes in which the excitation and emission 
wavelengths do not overlap. 
ANTIBODY STRUCTURE AND CHEMISTRY 
Antibodies, also called immunoglobulins, are proteins produced by the immune system for 
the defense of the organism against foreign species. They consist mainly of amino acids 
but also contain varying amounts of carbohydrate residues (3-12%), whose biological role 
is not well understood. Immunoglobulins are made of two heavy and two light chains of 
amino acids, forming a characteristic Y-shape. Disulfide bridges hold the heavy chains 
together to form the Y, whereas each light chain is bound to a branch of the Y to obtain the 
final structure (see Figure 5). The extremities of the Y branches have a well-defined 3-
dimensional shape, which is designed to specifically bind a target, or antigen, by a lock-
and-key mechanism. Potentially harmful foreign species (the keys) are therefore 
recognized by the immunoglobulins (locks) in the presence of numerous other molecules, 
and subsequently deactivated upon formation of a very stable immunocomplex. The very 
high antigen specificity of immunoglobulin is achieved thanks to a complex 3-dimensional 
arrangement of the amino acids, where a perfect match is obtained. The shape, the polarity 
and the electric charges of the key have to fit precisely into the lock (see expanded view in 
Figure 5). The stability of the overall antibody structure relies on a cooperative effect of 
numerous weak interactions between side chains of amino acids in the protein backbone.  
The sum of all weak interactions gives a strong structure. However, perturbation of a few 
weak interactions upon changes in pH or ionic strength, or chemical modification, may 
result in important changes in the tertiary shape of the immunoglobulin, and perhaps the 
loss of its affinity for a target.  
Each target requires a different recognition structure, and therefore a great variability is 
observed at the ends of the arms of a set of immunoglobulins. However, the rest of the 
protein shows little variation. Thus, immunoglobulin structure is split into two regions, one 
of variable composition, the other of constant composition (see a and b in Figure 5). 
Immunoglobulins are classified into five classes (IgG, IgA, IgM, IgD and IgE) on the basis 
of the composition of their constant region. For a given animal, all immunoglobulins of a 
given class have essentially the same constant region, which is slightly different from those 
of another class. However, interspecies variations are observed for immunoglobulins, e.g. a 
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goat may produce a goat anti-mouse IgG, which specifically binds any IgGs of a mouse, 
without interacting with IgGs from other animals. 
 
a
b
 
Figure 5: Schematic structure of an immunoglobulin protein. Two heavy chains 
(black) are linked by disulfide bridges (dotted lines) in the central part, which is 
known as the Hinge region. The bottom part of the protein (all black) is known as Fc 
region. Light chains (grey) are bound to the heavy chains by other disulfide bridges. 
Letters a and b indicate the variable and constant regions, respectively. The tips of the 
variable regions exhibit a specific tertiary structure, in which an antigen strongly 
interacts (see arrow). The expanded view shows in more detail how the antigen fits 
into the antibody. Electrical charges of the antigen (+/-) are locally counterbalanced by 
the protein, and hydrophobic domains (black lines) of the antigen and antibody also 
match well. 
A wide choice of commercially available specific antibodies can be purchased for 
qualitative and/or quantitative assays. Most antibodies are used to trace specific targets in 
tissues, liquids or surfaces. Whatever the assay conditions, the final stage requires antibody  
or antigen detection. For that purpose, antibodies are labeled prior to the assay by 
molecules characterized by their fluorescence, radioactivity, enzymatic activity, 
chemiluminescence or mass. Specific reagents have been developed to attach to proteins at 
almost any position. By far the most common coupling reactions take place with amino 
 groups. However, other chemically reactive groups, such as thiols, carboxylates, hydroxyls 
or carbonyls, may also be used as an anchor. Amine modification relies on the coupling 
reaction between an amino group of the protein with the activated group of a label. 
Chemical activation of the label is essential to obtain a sufficient amount of label on the 
protein. Historically, labeling with isothiocyanate-activated groups has been extensively 
used, for instance with fluorescein isothiocyanate, resulting in the formation of a stable 
thiourea bond (Figure 6a). More recently, N-hydroxysuccinimide- (NHS-) activated labels 
have become commercially available. NHS activation of a carboxylic group on the label 
yields very reactive species towards amines, producing an amide linkage (e.g. NHS-Cy5 in 
Figure 6b). Owing to their higher reactivity towards amines, labeling with NHS-activated 
molecules takes place 10 to 50 times faster than using the more traditional isothiocyanate 
chemistry.  
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Figure 6: Two examples of activated fluorescent molecules designed for coupling with 
an amino group of a protein (represented by a gray ellipse, not to scale). (a) 
Fluorescein isothiocyanate undergoes a coupling reaction to form a thiourea link, 
whereas (b) NHS-Cy5 is coupled upon formation of an amide bond. 
 protein contains numerous free amino groups. Some of them are buried in the protein 
ulk and hold the overall structure together by participating in stabilizing interactions with 
ther amino acids, whereas others are pointing out of the bulk and are therefore easily 
ccessible. Coupling of several labels on a single IgG first takes place on the accessible 
mino groups. However, forcing the coupling of numerous labels may result in the 
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modification of an amino group involved in a stabilizing interaction, and consequently in 
the modification of its chemical environment. For instance, the linkage of a Cy5 
fluorescent molecule, via NHS-Cy5 (see Figure 6b) modifies a small positively charged 
amino group into a bulky hydrophobic derivative that contains a negative charge. Under 
such an enormous change in chemical environment, the amino group loses its stabilizing 
interactions, and the tertiary structure of the protein is locally altered. The result of such a 
coupling reaction near the binding site of the antibody is the loss of its recognition ability. 
It is therefore important to tune the amount of label to insure sensitive detection, without 
destroying the antibody affinity for a target. 
During the coupling reaction between an antibody and an excess of amino-reactive 
activated label, most of the reagent is hydrolyzed by the OH- groups contained in water. 
Therefore, unbound label has to be removed from the antibody-containing solution either 
by exclusion chromatography or by immunoprecipitation. Exclusion chromatography is a 
separation technique relying on the use of a sugar-based gel that contains a controlled 
distribution of pores. Upon migration of a multi-component sample through the gel by 
gravitationally induced flow, small molecules have a chance to enter the pores and thus 
escape from the flow. Therefore, large molecules travel faster than small ones, and the 
sample components are separated by size. In the case of antibody labeling, the antibody is 
typically 150 times larger than the label, and fast separations are carried out easily. 
Separation by immunoprecipitation is based on the specific binding of IgG by protein A- or 
protein G-coated beads. The binding takes place at the IgG Fc region (see Figure 5), and 
the species-related small variations in that region are responsible for the varying affinity 
constants between protein A or G and IgGs. After incubation of the antibody-containing 
solution with the protein-coated beads, all IgGs are affinity-bound to the solid support. 
Undesired chemicals are washed away by centrifugation and IgGs are released by breaking 
the affinity bonds under acidic conditions, where the protein structures are altered due to 
an increased net charge. 
IMMUNOASSAYS 
The use of antibodies for clinical assays was first reported in the 1960's, with a competitive 
radioimmunoassay for insulin (24). Over the last 40 years, much progress in assay design 
has been achieved. Long-term efforts have been devoted to the replacement of radioactive 
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tracers by various fluorescent, chemiluminescent or enzyme labeled-tracers, yielding 
similar or better assay sensitivity (24). The first significant improvement was the 
development of antibody labeling and its application to "two-site" immunoassay 
(sandwich), where two antibodies bind an antigen at two different sites, a basic 
requirement for non-competitive immunoassays (see below). Later, the bioengineering of 
monoclonal antibody enhanced the sensitivity and the specificity of immunoassays. 
Immunoassays were first designed with a competitive format, with the non-competitive 
approach being developed later. In a competitive or "limited reagent" method, a limited 
number of antibodies are incubated with a sample containing a mixture of antigen and 
labeled antigen. Both species will compete for the few binding sites available on the 
antibodies. The antigen/labeled antigen ratio bound to the antibodies (or left out due to 
insufficient number of binding sites) is proportional to the initial ratio in the sample (see 
Figure 7). Hence, knowing the initial amount of labeled antigen added and determining the 
ratio of labeled to unlabeled antigen measured by competitive immunoassay, the original 
antigen concentration can be deduced.  
 
Antibody against     (antigen)
: Labeled antigen
only 1:1 ratio
/
(a) (b)
 
Figure 7: In a competitive immunoassay, the bound species reflect the ratio of antigen 
to labeled antigen in solution. (a) A sample containing only labeled antigen gives rise 
to a large label signal, whereas (b) in presence of a 1:1 ratio of labeled to unlabeled 
antigen in sample, the label signal drops by half. (This assumes that labeled and 
unlabeled species bind at the same rates. However, slight differences or loss of affinity 
may occur upon labeling.) 
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Competitive immunoassays are easily set up, but suffer from several disadvantages, 
including: (i) a limited sensitivity and working range, (ii) slow reaction kinetics, (iii) 
increased imprecision and (iv) the development of negative end-points. Negative end-
points are characterized by very low fluorescence signals for samples of high antigen 
content, which could be also caused by a faulty assay (e.g. due to pipetting or dilution 
error, use of degraded reagents or wrong automatic sample addressing).  
These disadvantages have been overcome by the introduction of a non-competitive 
immunoassay format, using a sandwich immunoassay and labeled antibodies. This assay 
format requires the use of two sets of antibodies, each one being able to recognize the 
antigen structure at a different location. Antigens from a dilute sample are concentrated 
upon binding to an excess of specific antibodies immobilized on a solid support. The 
affinity bond between the antigen and the primary antibody occurs at one antigen location. 
Then, a secondary labeled antibody is reacted with the bound antigen by affinity binding at 
another antigen location. The label signal that is measured is directly proportional to the 
amount of antigen pre-concentrated on the primary antibody.  
The final quantitative result from an immunoassay is obtained by recording the signal 
produced by the labeled partners (antigen or antibody) of the immunoreaction. 
Quantification is possible by recording either the free or the bound labeled partner, but 
these species first have to be physico-chemically separated. In homogeneous 
immunoassays, all partners are in solution, and the physico-chemical separation is often 
carried out by gel or capillary electrophoresis. Alternatively, the fluorescence produced by 
the bound species can be optically isolated by fluorescence polarization. However, 
immobilization of an immunoreaction probe on a solid substrate (e.g. wells, microtubes or 
beads) prior to running the assay forces the reaction to take place on the support and later 
reduces the separation step to a simple support washing, precipitation, or bead 
centrifugation. Moreover, the use of a heterogeneous format enables the preconcentration 
of the species in solution onto the solid support and therefore enhances the sensitivity of 
the assay. However, the uncontrolled adsorption of the solute onto the solid support surface 
can yield a significant background signal, which dramatically reduces the assay sensitivity 
(see Figure 8). Therefore, all heterogeneous immunoassays require the use of an efficient 
surface chemistry, which eliminates non-specific binding (NSB). The most popular 
approaches rely on the physisorption of bovine serum albumin or the use of diluted sample. 
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Surface chemistry can also help achieve better overall orientation of the antibodies for 
more efficient binding and enhanced affinity. 
Surface protected from NSBSurface unprotected from NSB
(a) (b)
 
Figure 8: (a) In the absence of a NSB-eliminating surface chemistry, antigen 
adsorption to the solid support surface during the immunoassay can result in a very 
large background signal. (b) However, the use of an appropriate surface treatment 
(grey layer) eliminates adsorption, and all benefits from a solid phase assay are 
obtained. 
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Goals of the work 
 
The overall goal of this work was to develop a single-use microfluidic device for the 
immunological detection of clinically relevant species, such as human IgG. 
Poly(dimethylsiloxane) (PDMS) was chosen as a material for channel fabrication because 
of its optical transparency, ease of use and possible modification with a stable 
physisorption-based coating. Electrokinetically driven sample transport was used for its 
ease of tuning individual fluid flow velocities in the channel network. Moreover, 
electrokinetic effects are responsible for transporting analyte and tracer at different 
velocities.  
For the purpose of developing an electrokinetically driven assay in a PDMS/glass 
microfluidic platform, electroosmosis in microchannels was studied. Several physico-
chemical treatments of the PDMS surface prior to sealing on glass were considered. The 
hydrophobic PDMS surface was shown to suffer from severe adsorption, and therefore the 
deposition of a passivating surface coating was investigated. Integration of biotinylated 
probes was possible in the outer layer of the three-layer biotin/neutravidin-based sandwich 
coating. Selective deposition of biotinylated anti-human IgG in the microfluidic platform 
was developed using a laminar flow-based patterning technique. The feasibility of a 
heterogeneous immunoreaction between anti-human IgG immobilized in the channels and 
Cy5-labeled human IgG in an electrokinetically transported liquid sample was 
demonstrated. Qualitative monitoring of the bound Cy5-human IgG was achieved by 
fluorescence microscopy. Quantitative measurements with a fluorescence scanner 
originally designed for arrays required changes in the chip design. Reproducibility and 
confidence in the assay results were enhanced by the implementation of an internal 
standard. This was done by co-immobilizing biotinylated anti-mouse IgG along with anti-
human IgG in the biospecific region of the chip. A competitive immunoassay for human 
IgG was set up, using Cy5-human IgG as bound tracer and Cy3-mouse IgG as internal 
standard. The ratio of Cy5 to Cy3 signal was used to assess the original human IgG 
concentration, while absence of Cy3 signal was indicative of faulty chip function. Human 
IgG concentration dependence was investigated under physiological and alkaline 
  19
conditions. Finally, monitoring of serum human IgG levels of patients and its potential 
application to diagnostics was investigated. 
Most of the work done in this project has been presented in two articles. Therefore, the 
early results that are not covered by the articles will be presented in detail and a short 
summary of the published work will follow. For more details, the articles have been 
attached in their original form in the appendices.  
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Experimental section 
 
This section describes the methodologies that were used to conduct the experiments carried 
out during the first part of this project, which was not submitted for publication. 
Methodologies utilized in the rest of the work are included in the publications, copies of 
which are attached in this dissertation as appendices. 
MICROFLUIDIC DESIGN WITH STRAIGHT CHANNELS 
The channel layout depicted in Figure 9a was realized in a chromium mask (Delta Mask, 
Enschede, Netherlands). The design contained straight channels of varying width (10, 30, 
and 50 µm) and a longer, 30 µm wide channel laid out in a serpentine manner. In this 
particular design, current monitoring measurements could be performed in channels of 
varying width and length (4, 6.5 and 37.8 cm).  
 
30 m linesµ
50 m linesµ10 m linesµ
30 mµ 50 mµ10 mµ
(a)
(b)
 
Figure 9: (a) The design of the master used for PDMS channel microfabrication 
contains several straight channels of varying length and width. (b) Channel profile 
obtained after KOH wet etching for each channel width. 
PDMS MICROFLUIDIC PLATFORM PREPARATION 
Silicon wafer micromachining provided masters for polymer replication of the layouts 
presented in Figure 9a. After photolithography and photoresist development, the silicon 
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was KOH-wet-etched to obtain 19-µm-deep structures (see Figure 9b). Residual 
photoresist was dissolved in acetone, and rinsed off with isopropanol. Before replication, 
the silicon surface was treated with octadecyldimethylchlorosilane, and fixed in a specially 
designed holder. Dow Corning PDMS Sylgard 184 obtained from Distrelec (Nänikon, 
Switzerland) was prepared according to the manufacturer’s directions, by mixing 1 part 
catalyst with 10 parts base resin. The pre-polymer was poured onto the master and cured at 
65°C for 4 h. The finished PDMS slab was peeled off and 4-mm-diameter access holes to 
the channels were punched out using a cork borer. The replica was cleaned by ultrasonic 
treatment in isopropanol, followed by water (5 min each).  
PDMS was prepared in several forms, referred to as native, aged or plasma-oxidized, and 
then sealed to a Pyrex substrate to form a hybrid device refered to as PDMS/Pyrex system. 
The native PDMS channels were obtained by using replicas produced as described above 
without further treatment. Aging of PDMS relied on a 12-hour thermal treatment at 115°C, 
followed by ultrasonic cleaning in isopropanol and water (see details above). Channels 
were formed by sealing the PDMS replica onto an unstructured AF45 glass wafer (Schott, 
Feldbach, Switzerland)). Prior to sealing, the glass substrate was degreased in hexane (5 
min), treated in aqueous HCl 5% (5 min) to render the surface hydrophilic, and rinsed in 
water. Glass and PDMS substrates were dried under vacuum (5.10-2 mbar) for 1 h. 
Reversible sealing of PDMS on glass was realized without further treatment. Plasma-
oxidized channels were obtained upon plasma oxidation of both substrates prior to sealing. 
RF-induced 100 W oxygen plasma treatment was carried out for 15 s in a Plasmalab 
80plus (Oxford Instruments, Bristol, UK) in 0.3 mbar O2. Channels were filled with 50 
mM phosphate buffer (PBS; pH 7.4, containing 150 mM NaCl) until use. Prior to the first 
measurements, filtered (0.45µm), 0.1 M NaOH solution was flushed into the channels, and 
allowed to interact with the PDMS for about 90 minutes. Finally, the system was 
conditioned again in PBS and stored at RT. 
CURRENT MONITORING IN CHANNELS 
A complete set of measurements consisted of two types of experiments. First, the sealing 
quality and the cleanliness of the microchannels (absence of clogs) were assessed by 
establishing a current response curve at varying applied voltages. Channels and reservoirs 
were filled with a fresh 20 mM sodium phosphate buffer (pH 7.0), and the current was 
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measured at increasing voltages ranging from 0V to 8000V. After every 800 V increase, 
the system was allowed to stabilize for 10 s, before recording the current. If measured 
currents agreed with calculated values for the channel geometry and solution conductivity 
in question, good sealing and clear channels were assured. The electroosmotic mobility 
was then measured in the channels using a method based on current monitoring (23).  
Channels were flushed with a fresh 20 mM buffer. One reservoir was then filled with 
slightly diluted, 19 mM buffer, and 20 mM buffer was introduced into the opposite 
reservoir. Hydrostatic pressure-driven flows were avoided by filling the reservoirs to equal 
levels. Electroosmotic flow was then generated in such a way that the dilute buffer entered 
the channel. As this buffer replaced the 20 mM buffer, current flowing through the channel 
was recorded and filtered using a digital low-pass filter operating at 30 Hz. After current 
signal stabilization, reservoirs were conditioned with fresh buffers and the reverse 
experiment was carried out. The electroosmotic flow velocity could then be calculated for 
both experiments by dividing channel length by the time required for the current to reach a 
stable value, at which point all buffer solution in the channel had been replaced. 
Electroosmotic flow velocity measurements were repeated using varying electric fields. 
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Results and discussion 
 
In this section, the results obtained during the first part of the project are presented in detail 
and their implications for the following work are discussed. Then, the key points for the 
rest of the work are summarized. More information about this latter part of the work is 
available in the appendices of the dissertation. 
PART I: ELECTROOSMOTIC MOBILITY IN PDMS CHANNEL 
When electroosmotic mobility is determined by current monitoring, a slightly diluted 
buffer enters the channel and replaces the same buffer at its original concentration. The 
concentrations of the buffer used should vary by no more than 5 %, to ensure that the 
assumption of a constant ζ potential is valid. As the buffer of lower ionic concentration 
enters the channel, the current flowing through the channel decreases gradually until the 
diluted buffer reaches the channel end (see Figure 10). Afterwards, the current becomes 
stable again.  
The electroosmotic flow velocity is calculated by dividing the time required to reach a 
steady current by the length of the channel.  The electroosmotic mobility is then calculated 
using Equation 2, where veo is the electroosmotic flow velocity, µeo the electroosmotic 
mobility (see Equation 1) and E the electric field.  
Ev eoeo ⋅= µ            [2] 
Electroosmotic velocities were measured for several electric fields ranging from 300 to 
1100Vcm-1, and plotted versus the applied electric field to obtain a straight line. The slope 
of the line, which is the electroosmotic mobility, was obtained by linear regression. 
Day-to-day reproducibility of the electroosmotic mobility was investigated in native 
PDMS/glass devices with 20 mM phosphate buffer (pH 7.0). Intermittent measurements 
were carried out over a period of 38 days, with the channels stored filled with PBS buffer 
between measurements. Electroosmotic mobility was shown to decrease by 6 % over this 
period (see Figure 11a), with an initial value of 4.46.10-4 cm2V-1s-1. The variations in 
electroosmotic mobility between a series of native PDMS/Pyrex devices were shown to be 
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less than 10 % (see Figure 11b). The average electroosmotic mobility was found to be 
4.99.10-4 cm2V-1s-1. 
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Figure 10: Electroosmotic velocity determination by current monitoring relies on the 
introduction of a more dilute buffer into a channel (black solid line). The experiment 
can also be conducted in reverse, to monitor the introduction of a more concentrated 
buffer into a channel (grey solid line). Experimental conditions: 19 and 20 mM 
phosphate buffer in a 30 µm wide PDMS/glass channel, under an electric field of 500 
Vcm-1. 
The influence of surface treatment on the electroosmotic mobility was also investigated for 
a single, freshly prepared PDMS replica. Electroosmotic mobility was measured in the 
PDMS/glass device before and after thermal aging and after plasma oxidation. 
Electroosmotic mobility determination took place directly after surface treatment. 
Variations in electroosmotic mobilities were less than 10 % (see Figure 12). Plasma-
oxidized PDMS appeared more hydrophilic than the native or aged elastomer. Despite that, 
aging and plasma treatment of PDMS had no significant effect on EOF, other than to 
improve the precision of the measurements. Linear regression calculations to obtain the 
electroosmotic mobility also yielded an associated error value, which was highest for the 
native PDMS/glass channel (see Table 1). The observed electroosmotic mobility in 
PDMS/glass channels is the sum of contributions from both materials. Therefore, the 
unchanged glass surface may partially mask the changes accuring on the PDMS surface. 
Changes in PDMS surface may be investigated in a 100% PDMS channel. 
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Figure 11: (a) Electroosmotic mobility monitoring in a single native PDMS/glass 
device over a 38-day time period. All data were obtained using the same channel. (b) 
Variations in electroosmotic mobility between three freshly prepared native 
PDMS/glass devices, #1 (triangles, line: solid), #2 (crosses, line: long dash) and #3 
(downwards pointing triangles, line: short dash).  Data points for each device were 
obtained using channels of various cross-sections (30, 50, 70 µm lines, see Figure 9) 
available on the device. Straight lines were calculated by linear regression. 
  26
250 300 350 400 450 500 550 600 650 700
0.10
0.12
0.14
0.16
0.18
0.20
0.22
0.24
0.26
0.28
0.30
0.32
0.34
El
ec
tro
os
m
ot
ic
 fl
ow
 v
el
oc
ity
   
(c
m
 s
-1
)
Electric Field   (V cm-1)
 
Figure 12: Electroosmotic flow velocity monitoring in a single PDMS/glass channel in 
a native form (squares, line: solid), after thermal aging (downward pointing triangles, 
line: long dash) and after plasma oxidation (upward pointing triangles, line: short 
dash). Electroosmotic mobility determination took place directly after surface 
treatments. Data points for each device were obtained using channels of various cross-
sections (30, 50, 70 µm lines, see Figure 9) available on the device. Straight lines were 
calculated by linear regression. 
 
Table 1: Calculated electroosmotic mobilities as a function of the surface treatment. 
Values, errors and correlation coefficients were all calculated by linear regression. 
Device Measurements
Electroosmotic 
mobility 
(cm2V-1s-1) 
Std. Dev. on 
mobility 
(cm2V-1s-1) 
Correlation 
coefficient 
(linear regression) 
Standard 16 4.85.10-4 1.50.10-5 0.996 
Aged 16 4.31.10-4 5.13.10-6 0.9995 
Plasma-
treated 16 4.65
.10-4 7.07.10-6 0.9994 
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According to optical microscope observation, the thinner channels (10 µm) replicated into 
PDMS were occasionally damaged upon separation from the master. However, high 
replication quality was achieved for the 30 µm and 50 µm channels, as well as good EOF 
reproducibility according to current monitoring. Due to the large cross section of the 50 
µm channels, large currents were observed, giving rise to Joules heating effects at 
relatively low electric fields. Therefore, the optimal channel size was found to be about 30 
µm.  
Applications for diagnostic microfluidic chips require reproducible channel surfaces, 
which remain unchanged over extended period of time. Surface treatment such as thermal 
aging or plasma treatment appeared to have a minor influence on the electroosmotic 
mobility intensity. However, current monitoring measurements were shown to be more 
reproducible in aged and plasma-treated channels than in native channels. The monitoring 
of a neutral fluorescent marker in thermally aged channels showed that the hydrophobic 
PDMS surface suffered from severe adsorption problems. In plasma-treated channels, 
adsorption problems appeared to be eliminated, but the adsorptive properties of the 
oxidized surface changed dramatically within 9 h (see Appendix 1 for more details). As a 
result of these preliminary experiments, the use of thermally aged PDMS appeared 
preferable to native PDMS, due to its higher EOF reproducibility and long-term stability. 
The plasma oxidation approach was discarded, due to the resulting surface instability.  
The main conclusion drawn from these initial studies was that an appropriate surface 
treatment for thermally aged PDMS microfluidic platform had to be established, both to 
eliminate the adsorptive properties of the hydrophobic surface, and to make possible the 
analysis of hydrophobic samples in the channels. This led to the development of the three-
layer, biotin-neutravidin-based biopassivation coating, TERACOAT, described in the next 
section, and in Appendix 1. 
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PART II: DEVELOPMENT OF A PLATFORM FOR IMMUNOREACTION  
This part presents a summary of the work that aimed at development of a platform for 
immunoreaction. The original article is provided in Appendix I (or Linder V., Verpoorte 
E., Thormann W., de Rooij N.F., Sigrist H. Anal. Chem., 2001, 73, 4181-4189.). 
PDMS surface modification – TERACOAT  
Handling of biological samples in PDMS/glass channels using electrokinetic sample 
transport was the starting point of this project. To that end, electroosmotic mobility was 
investigated by the current monitoring method and by neutral fluorescent marker 
displacement. The neutral dye, tetramethylrhodamine-dextran, was successfully used for 
electroosmotic mobility determination in Pyrex channels. However, when applied to 
PDMS/glass channels, tetramethylrhodamine-dextran appeared to adsorb to the elastomer 
surface. Further experiments showed that many constituents of biological fluids, such as 
proteins, were adsorbing onto the elastomeric surface as well. Thus, the deposition on 
PDMS of a coating made of three successive layers of biopolymers was investigated. The 
strong adsorptive properties of PDMS were exploited for the physisorption of biotin-
conjugated goat anti-mouse IgG. Neutravidin was then linked to biotin by affinity 
interaction, producing a second layer. Neutravidin is a bioengineered derivative of avidin 
that is neutral under physiological conditions, and was used instead of streptavidin or 
avidin to avoid possible interactions with charged molecules in solution. Finally, a layer of 
biotin-conjugated dextran was bound to unoccupied biotin-binding sites of the tetravalent 
neutravidin. The overall surface treatment was called TERACOAT (referring to TERnary 
Affinity COATing), see Figure 13a. Surface modification considerably decreased 
adsorption of low and high molecular mass substances to channel walls, while maintaining 
a modest cathodic electroosmotic flow. A surface passivation based on IgG physisorption 
was investigated because IgGs have a strong hydrophobic interaction with materials such 
as PDMS. And the use of biopolymers as blocking agent was found to be efficient to 
prevent adsorption of other biopolymers on the treated surface. 
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The long-term stability of TERACOAT in 6.74 mM tetraborate buffer (pH 9.3) was 
investigated by CZE over one month. Chips were stored filled in running buffer at room 
temperature. Detection times of tetramethylrhodamine dextran were shown to decrease 
about two-fold, the largest drop being observed during the first hundred hours. RSD values 
of detection times for each set of 10 measurements were found to be less than 2 %, 
indicating that operation of the chip was reproducible on the hour time scale. For all these 
experiments, the shape of the tetramethylrhodamine-dextran peak did not change. Thus, the 
favorable passivation properties of TERACOAT appeared to be stable under CZE 
conditions over longer periods of time.  
On-chip heterogeneous immunoreaction - TERASYS 
A variation of TERACOAT deposition enabled the selective deposition of antibodies at 
specific locations in the channel network. This surface preparation was named TERASYS 
(referring to TERnary Affinity SYStem). The first layer (biotin-conjugated goat anti-
mouse IgG) and second layer (neutravidin) were deposited as described above for 
TERACOAT. In the third layer, the channel network was partially coated with biotinylated 
goat anti-mouse antibodies to be used later for the immunoassay, and the remaining area 
was coated with inert biotin-conjugated dextran, see Figure 13b. The spatial resolution of 
the immobilized biomolecules was achieved using a flow patterning technique. Reservoirs 
1 and 3 (numbering according to Figure 14a) were filled with a solution of biotin-
conjugated dextran, and a solution of biotinylated goat anti-mouse IgG was pipetted into 
reservoir 4. Suction pumping at reservoir 2 generated three converging laminar flows 
towards vacuum. Biotinylated species attached to the neutravidin surface according to the 
flow profiles. Thus, a strip of antibodies was immobilized between reservoirs 4 and 2, 
while side channels were covered with dextran (as shown in Figure 14a).  
Immunoreaction between immobilized goat anti-human IgG and Cy5-human IgG was 
investigated. A solution of Cy5-human IgG (200 µg/mL (1.33 µM) in PBS) was 
electrokinetically transported from reservoir 1 to 3 (see Figure 14b). It is interesting to note 
that, under the chosen conditions, Cy5-human IgG is negatively charged and migrates in 
the direction opposite to EOF. Incubation under electrokinetic conditions was carried out 
for 6 min, and the sensing area was subsequently rinsed with running buffer for 1 min (see 
 Figure 14c). Three important pieces of information can be extracted from the sensing area 
imaged by the fluorescence scanner (Figure 15a). 
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PART III: IMMUNOASSAY FOR HUMAN IgG  
This part presents a summary of the work that involved the implementation of an internal 
standard on the chip, and the development of an immunoassay for human IgG. The original 
article, is available in Appendix II (or Linder V., Verpoorte E., de Rooij N.F., Sigrist H., 
Thormann W. Electrophoresis, 2002, in press). 
Incorporation of an internal standard into the TERASYS platform 
The TERASYS platform characterized earlier was further developed for the analysis of 
human IgG in serum by a competitive immunoassay. A potential clinical application of the 
TERASYS chips requires an enhanced reproducibility for the immunoreaction (e.g. much 
less than 18 %) and a high level of confidence in the results obtained. TERASYS chips 
described in this contribution are single-use disposable devices that cannot be calibrated or 
tested prior to use. Therefore, an internal standard was implemented in the TERASYS 
chips, by immobilizing biotinylated goat anti-mouse IgG and biotinylated goat anti-human 
IgG in equal amounts in the sensing area. Samples containing 665 nM Cy3-mouse IgG and 
665 nM mixtures of Cy5-human IgG/human IgG (different ratios) were then reacted in the 
chips. Recording fluorescence using 532 and 635 nm laser lines provided individual 
measurements for Cy3 and Cy5. An abnormally low or missing Cy3 signal indicated that 
TERASYS was not working, while minor chip-to-chip variations were compensated for by 
using the Cy5/Cy3 signal ratio. 
On-chip competitive immunoassay for human IgG 
Competition in the human IgG immunoassay took place in TERASYS chips, but assay 
sensitivity had a strong dependence on the running buffer pH. Electrokinetic transport of 
sample was very different in physiological buffer (pH 7.4) than under alkaline conditions 
(pH 9.3). Unlabeled and fluorescently labeled IgGs were observed to migrate very slowly 
in a direction opposite to electroosmotic flow at pH 7.4. However, at pH 9.3, the observed 
migration was with the electroosmotic flow. Typical net mobilities of Cy3-mouse IgG 
were about 6.5.10-5 cm2s-1V-1 towards the cathode at pH 9.3 and towards the anode at pH 
7.4. 
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Fluorescent labeling of IgG introduced additional negative charges to the IgG molecules. 
Therefore, when migrating against the EOF at pH 7.4, Cy5-human IgG reached the 
intersection first and could react initially with immobilized antibodies without competition. 
Competitive immunoassay therefore takes place only with the remaining free binding sites, 
resulting in poor assay sensitivity. However, at pH 9.3, both labeled and unlabeled human 
IgG migrated with EOF, with the less negatively charged unlabeled species arriving first at 
the intersection. Hence, initial human IgG binding took place under non-competitive 
conditions, yielding enhanced assay sensitivity, as shown in Figure 16. 
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Figure 16: Calibration curve for human IgG competitive immunoassay. Sensitivity 
was enhanced when changing pH from 7.4 (dotted line) to 9.3 (solid line), which 
resulted in arrival of unlabeled antigen at the intersection prior to labeled antigen, 
leading to increased binding of the former species. 
The immunoassay of the synthetic preparation of human IgG under alkaline conditions 
enabled detection down to 50 nM (7.5 µg/mL), with 6.8 % RSD (a value calculated by 
averaging RSD from 4 sets of data, ntot = 17). The incubation time (not optimized) was set 
to 7 min to insure saturation of all binding sites on the surface. The heterogeneous format 
of the assay may enable the analysis of more dilute samples by allowing longer incubation 
times. 
The long-term stability of fully prepared TERASYS chips was investigated using two 
means of chip storage, (i) at 4°C in PBS and (ii) at –20°C after buffer vacuum evaporation. 
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After a two-month storage period, immunoassays using a 1:1 Cy3-mouse IgG/Cy5-human 
IgG solution were performed under alkaline running conditions. Data obtained in chips 
stored at 4°C compared well with measurements made in fresh TERASYS chips. However, 
in the reconstituted dry-stored chips, the surface passivation was not active anymore, and 
an immunoassay could not be carried out. 
IgG monitoring in human serum 
Analysis of human serum failed when using the same experimental conditions as for the 
data presented in Figure 16. However, determination of IgG in human serum was shown to 
be possible using a different sample preparation. The four sera obtained from the clinical 
chemistry laboratory of the Inselspital (Berne, Switzerland) were then prepared with a 
larger excess of tracer (final human IgG concentration were 5.11, 8.50, 19.72 and 35.94 
nM). Each sample was analyzed on four, freshly prepared, TERASYS chips. From the 16 
runs, the data of 6 chips were discarded after weak internal standard signals indicated a 
faulty chip. Results obtained in the properly working TERASYS chips showed a 
concentration dependence for human IgG (Figure 17). A plot of the data obtained with 
synthetic and serum samples on the same scale showed that the dynamic range for 
determination of human IgG concentration in real samples was substantially smaller than 
for synthetic samples. Further work is required to properly elucidate the reasons for this 
pronounced sensitivity to sample matrix effects. Two phenomena are likely to be 
responsible: (i) an interfering species contained in serum sample may affect the antigen 
binding in TERASYS, or (ii) the absorption of serum component on the coating may affect 
the electrokinetic mechanism of sample delivery, and hence, assay sentivity.  
The exact quantification of human IgG in serum was found to be difficult, due to the high 
RSD at a low human IgG concentration and the low concentration sensitivity at higher IgG 
levels. However, the data obtained for the two patients with normal IgG levels can be 
clearly distinguished from the data of the two other patients, who had elevated IgG levels 
caused by a chronic infection and cancer myeloma, respectively. The limit of detection for 
human IgG in serum samples was estimated at about 5 nM. 
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Figure 17: Concentration dependence obtained in TERASYS chips for human IgG in 
synthetic (circles, curve for the sake of clarity) and in serum (squares) samples. 
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Conclusion 
 
Preliminary experiments showed that thermally aged PDMS was a more promising 
material than native or oxygen-plasma-treated elastomer. A simple coating procedure has 
been established to passivate the hydrophobic PDMS surface, while maintaining a residual 
surface charge capable of producing a modest EOF. The coating deposited in PDMS/glass 
microchannels is stable in biological fluids and detergent-free buffers. Strongly reduced 
adsorption (low NSB) makes its use possible for heterogeneous affinity assays. The 
coating concept enables integration of any biotinylated probe into the third layer. 
Moreover, the probe-patterning technique used in the channel network permits the 
quantification of bound target, NSB to the coated surface, and background fluorescence, on 
a single TERASYS device. Feasibility of an immunoreaction was demonstrated with an 
anti-human IgG/Cy5-human IgG system. The signal-to-noise ratio was found to be 206 for 
a sample containing 1.33 µM Cy5-human IgG, while labeled antigen NSB to the treated 
surface was effectively suppressed. Bound antigen quantification showed that fluorescence 
intensity was reproducible chip-to-chip and day-to-day. Data from eight disposable chips 
showed a relative chip-to-chip standard deviation of 18 %.  
The anti-human IgG/Cy5-human IgG model used for immunoreactions was further 
developed into an immunoassay for human IgG. Performance of the assay was enhanced 
by the implementation of an internal standard. As a result, disposable microfluidic 
platforms for a heterogeneous competitive immunoassay of human IgG employing Cy5-
human IgG as tracer and Cy3-mouse IgG as internal standard were obtained. Electrokinetic 
sample transport was applied in order to exploit a small difference between the net 
mobilities of analyte and tracer, thereby achieving a preconcentration of human IgG on the 
solid support that led to an increase in the sensitivity of the immunoassay at pH 9.3. The 
overall quality of the disposable chip and the performance of the immunoreaction were 
controlled by monitoring the fluorescence of the bound internal standard. Runs with 
abnormal internal standard response were discarded. Furthermore, data evaluation was 
based upon calculation of the ratio of fluorescence intensities of bound tracer and bound 
internal standard (Cy5-human IgG and Cy3-mouse IgG, respectively), an approach that 
reduced chip-to-chip variations. Using synthetic samples, the concentration dependence in 
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the range from 0 to 500 nM human IgG was shown to provide reproducible Cy5/Cy3 
signal ratios between 2 and < 0.5, associated with an average RSD of 6.8 %. The 
incorporation of the internal standard is thereby demonstrated to provide the level of 
confidence required in clinical analysis. Furthermore, chips wet-stored at 4 °C over a two-
month period were found to perform comparably to new chips, whereas dried chips stored 
at – 20 °C and re-hydrated prior to use could not be used at all.  
The analysis of patient sera showed that the immunoassay platform behaved differently in 
the presence of serum-based samples. Using the same conditions as for the synthetic 
samples in the 0 – 500 nM range, no concentration dependence was noted. With a larger 
excess of tracer, a small dependence on IgG concentration was noted but did not permit 
exact quantification of IgG in these samples. However, patients with normal IgG levels 
(4.4 – 8.9 nM) could be clearly differentiated from patients with elevated IgG 
concentrations (10 - 50 nM).  
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Outlook 
 
The data presented in this work shows that TERASYS can form the basis of a 
heterogeneous immunoassay for human IgG. The IgG immunoassay performed as 
described previously could potentially find an application in screening patients for elevated 
IgG levels. Real-time observation showed that the immunoreactions take place very 
quickly in the TERASYS chips, and that strong signals are obtained within 30 seconds. 
Therefore, the incubation time of the human IgG immunoassay could be shortened 
significantly. This aspect could be further exploited for a screening test.  
In diagnostic labs, total IgG level is usually assessed by nephelometric assays. In a second 
stage, patient sera with high IgG levels are further tested for a gammopathy determination, 
which is carried out by immunofixation electrophoresis or immunoelectrophoresis. The 
latter analysis enables the distinction between cancer- and inflammation-related diseases. 
TERASYS chips cannot compete directly with the nephelometric assays. However, the 
concept could be adapted to carry out several parallel immunoassays, in a microfluidic 
system containing several intersections. The ability to pattern selectively each intersection 
with a specific antibody would allow a sample to be tested for many clinically relevant 
species at once, e.g. for gammopathy determination. Such a device would represent as a 
new tool in the diagnostics field, where a single chip could be used for screening patient, 
and at the same time carry out a gammopathy determination, see Figure 18. However, 
experiments showed that TERASYS chip response varied when changing from synthetic 
samples to serum-based samples. A new sample preparation protocol did not resolve this 
problem, though that a better understanding of the reasons for these variations will be 
required for a real application. Moreover, biotin-dextran in TERACOAT was replaced by 
biotin-IgG in TERASYS, without looking at the NSB suppressing capability of the new 
coating. A detailed study of the TERASYS surface seems would be appropriate.   
Alternatively, the monitoring of pM antigen concentrations could be attained with longer 
incubation times, or by extending the delay between analyte and tracer delivery. Variation 
in the length of the sample delivery channel would be one simple way of controlling the 
start of sample addition.  
  40
Using the actual chip setup, the main drawback of the system is the fluorescence detection 
of the immunocomplex. Signal measurement accounts for about 50 % of the total analysis 
time (including channel coating). The high sensitivity achieved using the confocal 
microscope setup built into the array scanner is required to acquire the signal through the 
PDMS layer. However, the z-axis alignment of the collection lens is time consuming, and 
has to be repeated for each new structure because of the varying chip-to-chip PDMS 
thickness. Therefore, the use of an inverted setup, where light excitation and collection 
takes place through the bottom glass substrate would make the light path through the chip 
identical for all devices. Such a simplification of the optical detection would ultimately 
enable automated detection.  
 
Figure 18: The TERASYS chip (a) concept could be modified into a fish bone-like channel 
network (b), where different antibodies are immobilized in each vertical channel. Serial sample 
delivery at each cross provides a chip for parallel immunoassays.
Gammopathy determination
(Monospecific antibodies: IgG, IgA,
IgM, κ, λ)
Screening for elevated 
level of antibodies
(a)
Antigen 
delivery
Antigen 
delivery
(b)
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ABSTRACT 
A microfluidic platform for a heterogeneous competitive immunoassay of human 
immunoglobulin G (IgG) employing Cy5-human IgG as tracer and Cy3-mouse IgG as 
internal standard was developed. The device consisted of microchannels made of 
poly(dimethylsiloxane) and glass which were patterned with antibodies against human IgG 
and mouse IgG. Electrokinetic sample transport was employed in order to exploit the small 
difference between the net mobilities of analyte and tracer, thereby achieving favorable 
conditions for the performance of the competitive immunoreaction. The overall quality of 
the disposable chip and performance of the immunoassay were controlled by monitoring 
the fluorescence of bound tracer and bound internal standard. Analyses with an insufficient 
internal standard response were discarded, and immunoassay data evaluation was based on 
the ratio of tracer and internal standard fluorescence. Using synthetic samples in the range 
from 0 to 80 µg/mL IgG and alkaline running conditions, a concentration-dependent 
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response with reproducible Cy5/Cy3 signal ratios (average RSD of 6.8 %) was obtained. 
Chips stored with solution in the channels at 4 °C over a two-month period were found to 
perform like freshly prepared chips, whereas chips stored dry at – 20 °C and rehydrated 
prior to use could not be employed. The analysis of patient sera showed that the 
immunoassay platform behaved differently in the presence of serum-based samples. Using 
the same conditions as for the synthetic samples, no concentration dependence was noted. 
With a large excess of tracer, however, an IgG concentration dependence was observed, 
permitting distinction of samples of patients with normal IgG levels (8-16 mg/mL) from 
those with elevated IgG concentrations (> 16 mg/mL). 
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1 INTRODUCTION 
Monitoring of immunoglobulin G (IgG) in serum is of clinical relevance. IgG 
concentrations between 8 and 16 mg/mL are considered normal, whereas elevated levels 
may be associated with chronic infection (polyclonal elevations) or cancer (monoclonal 
elevations). Thus, methods to monitor the total amount of IgG and to allow the distinction 
between polyclonal and monoclonal gammopathies are required [1]. In the past, many 
techniques have been employed for monitoring total human IgG in body fluids, including 
radial immunodiffusion and electroimmunoassays (also known as rocket immunoassays), 
methods that rely on precipitation reactions between antigen and antibodies [1]. Nowadays, 
quantification of IgG is carried out by nephelometric or turbidimetric immunoassays, 
techniques that are fast, automated and reproducible. Furthermore, different types of 
sandwich immunoassays for IgG have been described using various antibody labels, such 
as alkaline phosphatase [2], radioactive isotopes [3], and fluorophores [4]. Another 
approach reported relies on affinity chromatography using a fused-silica capillary packed 
with protein G coated beads [5]. Monoclonal gammopathies are assessed by either 
immunoelectrophoresis or immunofixation electrophoresis. These semi-quantitative 
approaches enable distinction between a monoclonal, an oligoclonal and a polyclonal 
gammopathy. During the past decade, analysis of serum proteins by capillary zone 
electrophoresis has been introduced and applied to the monitoring of monoclonal IgG 
using immunosubtraction [6,7]. 
Starting in the early 90’s with the integration of capillary electrophoresis techniques onto 
glass chips, an increasing number of applications have been implemented on microfluidic 
platforms with the goal of developing configurations for high-throughput or point of care 
analyses. Among these developments, the performance of homogeneous immunoassays in 
microfluidic-based instrumentation has been investigated and applied to the analysis of 
cortisol [8] and theophylline [9,10] in serum. Mouse IgG has been analyzed on planar glass 
structures using enzyme-labeled anti-mouse antibodies and chemiluminescence detection 
[11]. Competitive heterogeneous immunoassays for the pregnancy hormone chorionic 
gonadotropin and theopylline have been implemented in microchannels using evanescent 
field detection [12]. In a different approach, secretory human immunoglobulin A [13] and 
carcinoembryonic antigen [14] have been analyzed on polystyrene micro-beads clustered 
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behind a dam microfabricated in a microfluidic channel. Poly(dimethylsiloxane) (PDMS) 
microchannel surfaces have been modified with phospholipids for the detection of anti-
dinitrophenyl antibodies [15] or with proteins for sheep IgM quantification by an ELISA 
[16]. Similarly, a Pyrex microfluidic reaction chamber has been modified with protein A in 
order to produce a platform for IgG binding, which has been used for rabbit IgG detection 
in buffer [17]. Surface patterning has been applied to PDMS, thereby enabling 
micromosaic immunoassays to be carried out for chicken IgG [18], or providing a surface 
for human IgG binding [19]. 
In previous work from our laboratories, PDMS/glass chips featuring a surface treatment 
comprised of a three-layer, biotin-neutravidin-based sandwich coating were developed and 
applied to an electrokinetically driven, heterogeneous immunoreaction for human IgG [19]. 
Continuation of this project was geared towards the performance of an immunoassay for 
human IgG on a disposable PDMS/glass chip. For that purpose, incorporation of an 
internal standard, electrokinetic sample delivery and analysis of synthetic and patient 
samples were studied. The data presented in this paper are the first results of a 
heterogeneous competitive immunoassay for human IgG performed on disposable, surface 
biopassivated PDMS/glass chips and thereby demonstrate the feasibility of developing 
microfluidic platforms for the rapid determination of elevated IgG levels in human serum. 
2 MATERIALS AND METHODS 
2.1 Materials and reagents 
Microscope slides 26x76 mm2 made of polished AF45-glass were purchased from Schott 
Schleiffer (Feldbach, Switzerland). The Dow Corning PDMS kit Sylgard 184 was obtained 
from Distrelec (Nänikon, Switzerland). The Cy5 antibody labeling kit was purchased from 
Amersham Pharmacia Biotech (Dübendorf, Switzerland). Biotin-conjugated dextran (10 
kDa) and neutravidin were Molecular Probes products purchased from Juro Supply 
(Luzern, Switzerland). Biotin-conjugated goat anti-mouse IgG and biotin-conjugated goat 
anti-human IgG were manufactured by Pierce (Rockford, IL, USA) and obtained from 
Socochim (Lausanne, Switzerland). Purified human IgG was obtained from ICN 
Biomedicals GmbH (Eschwege, Germany). Cy3-conjugated mouse IgG was manufactured 
by Jackson Immunoresearch Laboratories (West Grove, PA, USA) and purchased from 
Milan Analytica (La Roche, Switzerland). Other reagents were of research grade. PBS 
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refers to phosphate buffer saline containing 50 mM phosphate buffer (pH 7.4) and 150 mM 
NaCl. Biotin-conjugated goat anti-mouse IgG contained bovine serum albumin which was 
removed as described in [19] using protein G-coated Sepharose beads (Fast Flow 4B; 
Sigma, Buchs, Switzerland) and PD-10 columns prepacked with Sephadex G-25M 
(Amersham Pharmacia Biotech). 
2.2 Tracer and sample preparation 
The tracer, Cy5-labeled human IgG, was prepared according to the manufacturer’s 
instructions, using the antibody-labeling kit comprising NHS-activated Cy5 dye. By 
varying the initial amounts of human IgG and/or activated dye in the reaction vial, 2 to 9 
Cy5 molecules could be attached to each IgG molecule. Two batches of Cy5-human IgG 
were used in this study (referred to as batches I and II), having a dye-to-protein molar ratio 
of 2.2 and 2.9, respectively. The extent of labeling was determined according to the 
manufacturer’s instructions using UV/VIS spectroscopy.  
Synthetic samples employed to evaluate the concentration dependence of the immunoassay 
at physiological and alkaline conditions were prepared from 200 µg/mL solutions of Cy3-
mouse IgG (internal standard), unconjugated human IgG, and Cy5-human IgG (batch I and 
II, tracer) in PBS. If not stated otherwise, unconjugated human IgG and Cy5-human IgG 
were mixed to obtain solutions comprising analyte/tracer ratios of 0, 0.125, 0.250, 0.500 
and 0.800. Finally, 200 µL of the latter solution was mixed with 200 µL of Cy3-mouse 
IgG. Human serum samples were prepared differently. Serum was diluted 150 times with 
PBS, and 5 µL of diluted serum was mixed with 195 µL of Cy5-human IgG solution (batch 
II). Then, 25 µL of the latter solution was mixed with 25 µL of Cy3-mouse IgG. The total 
serum dilution was 12’000-fold. Depending on the human IgG concentration in serum, the 
total IgG concentration (IgG stemming from serum, tracer and internal standard) in the 
final sample varied between 198 and 202 µg/mL. Matrices of synthetic and serum samples 
were essentially the same (100 % and 99.9 % PBS, respectively). 
2.3 PDMS/glass chip preparation 
Preparation of the PDMS/AF-45 glass devices has been described elsewhere [19]. Briefly, 
the channel design (see Fig. 1) was transferred onto a silicon wafer by photolithographic 
techniques. The master for PDMS replication was obtained by deep reactive ion etching of 
  
the wafer where it was not coated by photoresist. Liquid PDMS pre-polymer was poured 
onto the silicon master and cured 4 h at 65°C. Polymerized PDMS replicas of about 0.8 
mm thickness were peeled off, and at the channel ends, 4-mm access holes were punched 
out using a cork borer. Prior to reversible sealing with an AF45-glass slide, replicas were 
thermally treated at 115°C for 12 h, and cleaned in isopropanol and water.  
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pumping at reservoir 2 generated three converging laminar flows toward vacuum. 
Biotinylated species attached to the neutravidin surface according to the flow profiles. 
Thus, a strip of antibodies was immobilized between reservoirs 4 and 2, while side 
channels were covered with dextran (as shown in Fig. 2a and Fig. 3a).  
2.4 Instrumentation for electrokinetically driven immunoassay  
The chip was mounted on a custom-made PMMA holder that fitted onto the XY table of an 
inverted fluorescence microscope (Axiovert S 100; Carl Zeiss, Zürich, Switzerland). 
Optics located below the table enabled qualitative observation during the assay. A detailed 
description of this instrumentation has been reported elsewhere [19]. Briefly, fluorescence 
microscope observation was possible at different wavelengths, using the available set of 
filters for fluorescein (blue light excitation), Cy3 (green) or Cy5 (red). The emission light 
was focused on a CF 8/4 DXC black-and-white CCD camera (Kappa, Gleichen, Germany). 
Above the chip, platinum electrodes ensured electric connection to the high voltage (HV) 
supply. A custom-made HV power source assembled by Goeckeler Electronique 
(Neuchâtel, Switzerland) was controlled by two DAQPad-6020E boards from National 
Instruments (Austin, TX, USA). The overall system was computer-controlled, using in-
house software written in Labview (National Instruments). 
2.5 Competitive heterogeneous immunoassay conditions for human IgG 
Immunoassay conditions at physiological pH (PBS, pH 7.4) and at alkaline pH (50 mM 
sodium tetraborate buffer, pH 9.3) were investigated (Fig. 2). TERASYS chips were 
conditioned with the appropriate buffer by maintaining a suction driven flow of buffer 
throughout the network during 1 min. Fig. 2 outlines schematically how antibodies were 
patterned onto the channel surfaces at the intersection, and how the immunoassay was 
subsequently carried out at physiological or alkaline pH. The large arrows in panels b) to e) 
indicate the direction of the electrokinetic transport of the antigens. It should be noted that 
at pH 7.4, the electrophoretic mobility of the negatively charged human IgG was large 
enough that it determined the overall transport direction of this species, which was 
opposite to the electroosmotic flow (EOF). At pH 9.3, the apparent mobility of human IgG 
was in the direction of EOF. When working with PBS, sample was pipetted into reservoir 
3, and electrokinetically transported towards reservoir 1 using a high electric field. 
Incubation at a much reduced electric field and a washing step followed.  
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Fig. 2: Schematic representation of the flow patterns and antigen transport for the IgG 
immunoassay. For the sake of clarity, the polarities (+, -) at the reservoirs are given 
relative to the electric potential at the channel intersection. Small arrows in panel a) 
mark the direction of pressure driven flow, whereas the large arrows in panels b) to e) 
indicate the direction of the electrokinetic transport of the antigens. (a) Bioprobe 
patterning: the biotin-conjugated antibodies were immobilized on the neutravidin-
coated surface. The immobilization pattern followed the laminar flow profiles 
generated by vacuum pumping at reservoir 2. (b),(c) Under physiological conditions, 
the immunoreaction took place at the intersection where antibodies were immobilized 
and in contact with sample (hatched area). (b) Sample (antigen) was electrokinetically 
delivered across the antibody-coated area. Side buffer flow was kept much smaller 
than sample flow, such that no flow patterning was observed at the cross. Sample was 
delivered to the intersection under an electric field of 300 Vcm-1 (75 s; -600 V at 
reservoir 3, -420 V at reservoirs 2 and 4, ground at reservoir 1). Incubation was carried 
out under an electric field of 60 Vcm-1 (360 s; -120 V, -84 V and 0 V at reservoirs 3, 
2/4 and 1, respectively). (c) Unbound antigen was removed by electrokinetic pumping 
(60 s; -72 V at reservoirs 1 and 3, -600 V at reservoir 2, ground at reservoir 4) without 
removing the bound antigen (hatched area). (d), (e) Under alkaline (pH 9.3) 
conditions, the same immunoreaction was carried out at the intersection. (d) Sample 
was electrokinetically transported across the immobilized antibodies and incubated 
with an electric field of 275 Vcm-1 (400 s; -600 V at reservoir 3, -120 V at reservoirs 
 2 and 4, ground at reservoir 1). (e) Unbound antigen was then washed away (60 s; 
-600 V at reservoirs 1, 2 and 3, and ground at reservoir 4). All reservoirs were finally 
rinsed with running buffer. 
Incubation and immunocomplex formation of Cy5-human IgG in a TERASYS chip at 
physiological conditions was observed using fluorescence microscopy (Fig. 3b and 3c). In 
case of alkaline conditions, sample was loaded into reservoir 1 and transport occurred 
towards reservoir 3 (no reduction of the electric field during incubation), followed by a 
washing step. A detailed description of the experimental conditions used for the two 
immunoassay formats is given in the legend of Fig. 2. 
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mechanism. Thus, proper alignment in the z direction was achieved by increasing the 
substrate thickness using strips of tape 200 µm thick applied along the edges of the device 
on the glass side, as is illustrated in Fig. 4. 
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wered the channel to fall into the focal plane of the lens. Fine adjustment 
was necessary to take into account the changes of the PDMS thickness. 
arried out in the region of interest using 532 and 650 nm diode lasers. 
escence intensity at 570 nm (Cy3) and 665 nm (Cy5) was quantified 
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individually for each scan across a circular area with 3 pixels (30 µm) in diameter using an 
image processing software (Imagene 4.01, Biodiscovery, Los Angeles, CA, USA). 
3 RESULTS AND DISCUSSION 
3.1 Incorporation of an internal standard into the TERASYS platform 
A clinical diagnostic test requires a high level of confidence in the results obtained. 
TERASYS chips described in this contribution are single-use disposable devices that 
cannot be calibrated or tested prior to use. Systematic control of the chips by optical 
microscopy may provide quality control during microfabrication steps. Similarly, 
TERASYS surface modification may be controlled by electrokinetic characterization [19]. 
Immobilized antibody activity and sample transport in the chip, however, cannot be 
controlled by these methods. Thus, the overall quality of the chip and the success of the 
immunoreaction were controlled using an internal standard that was implemented into the 
TERASYS platform. The third layer of the coating, where antibodies for recognition are 
located, was prepared with two different antibodies. Biotin-conjugated anti-mouse IgG and 
biotin-conjugated anti-human IgG were co-immobilized by flushing a 1:1 solution during 
the patterning step, while biotin-conjugated dextran was used for passivation of the side 
channels. At that stage, mass transport relied on suction pumping. Biotinylated antibodies 
were assumed to be bound in equal quantities to the neutravidin surface, and thus were 
equally reactive towards both IgG’s. A possible discrimination originating from unequal 
electrokinetic transport could thus be excluded. 
Samples subjected to the competitive immunoassay for human IgG contained Cy5-human 
IgG and Cy3-mouse IgG as tracer and internal standard, respectively. Cy3 and Cy5 
conjugates (for structures see Fig. 5) can be spectrally distinguished (excitation/emission at 
532/570 nm and 650/665 nm, respectively). The emission light of Cy3 (570 nm) cannot 
excite Cy5 and the fluorescence of Cy3 and Cy5 can thus be individually quantified. All 
samples were prepared with a fixed amount of Cy3-mouse IgG, which was equal to the 
total quantity of human IgG and Cy5-human IgG. The Cy5-to-Cy3 fluorescence signal 
ratio was determined and employed as the basis for data evaluation. Abnormal or lack of 
Cy3 signal showed that the TERASYS chip was not working properly (see below), while 
minor chip-to-chip variations were compensated for by using the signal ratio. Variations 
occurring from channel replication problems or surface chemistry are balanced by the co-
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immobilization of the two antibodies. A TERASYS platform of low anti-human IgG 
content will show a proportional reduction of immobilized anti-mouse IgG as well. 
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Fig. 5: Chemical structure of Cy3 (n=0) and Cy5 (n=1) labels after attachment to an 
IgG molecule (grey ellipse). The diagram is not to scale, since in reality IgG is about 
200 times larger than the label 
3.2 Electrokinetic sample transport and elucidation of the IgG concentration 
dependence 
For execution of the immunoassay in TERASYS chips, unconjugated and fluorescently 
labeled IgG’s were electrokinetically transported to the reactive area. At physiological pH, 
Cy3-mouse IgG and Cy5-human IgG were shown by fluorescence microscopy to be 
displaced towards the anode, i.e. against the EOF. The opposite behavior was observed in 
channels conditioned with 50 mM tetraborate buffer at pH 9.3, where the net displacement 
occurred in the direction of the cathodic EOF. Identical behavior was indirectly observed 
for unconjugated human IgG. For both cases, electrokinetic mass transport was very slow, 
indicating that electroosmotic and electrophoretic contributions to the observed IgG 
mobilities were similar. The net mobility of Cy3-mouse IgG was determined to be in the 
range of 5.10-5 to 8.10-5 cm2s-1V-1. At physiological and alkaline conditions (pH 7.4 and 9.3 
respectively), polyclonal IgG molecules are negatively charged. However, the exact 
charges are unknown. Introduction of Cy3 or Cy5 labels on an IgG molecule (see Fig. 5) 
increases the number of negative charges and the electrophoretic mobility of labeled IgG is 
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expected to be slightly higher compared to that of unconjugated IgG. As the net transport 
of IgG was found to be low (close to balance of electroosmotic and electrophoretic fluxes), 
relatively small changes of either of the electrokinetic contributions could have a 
significant impact on net solute mobility. 
In PBS conditioned chips, IgG’s were found to be displaced towards the anode (against 
EOF, Fig. 2b) and the more negatively charged molecules were thus transported faster. 
When a competitive immunoassay was carried out using the human IgG/Cy5-human IgG 
system, the labeled partner arrived first to the area comprising the immobilized anti-human 
antibodies. By the time unconjugated human IgG reached the immobilized antibodies, 
most of the binding sites were already occupied by the Cy5-human IgG. It appeared that 
only a small fraction of the binding sites were left available for competition. Therefore 
most of the large fluorescence signal recorded was irrelevant for the human IgG-to-Cy5-
human IgG ratio in the sample. Hence, the competitive immunoassay was almost 
concentration independent (see Fig. 6). In contrast, in the alkaline medium, IgG’s were 
electrokinetically displaced towards the cathode (direction of EOF) and the less negatively 
charged molecules were transported faster to the immunochemical reaction site.  
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Fig. 6: Concentration dependence of the competitive immunoassay assessed via use of synthetic 
samples comprising varying relative amounts of human IgG / Cy5-human IgG (batch I). 
Experiments conducted at physiological pH (squares, solid line) showed almost no concentration 
dependence, while good sensitivity was obtained for experiments carried out under alkaline 
conditions (circles, broken line). 
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Unconjugated human IgG reached the immobilized antibodies first and could be bound to 
the anti-human IgG without competition until Cy5-human IgG arrived as well. Samples of 
high human IgG content were able to bind almost all sites before arrival of Cy5-human 
IgG, yielding a very low fluorescence signal. On the other hand, only a few sites were 
bound by human IgG upon analysis of samples of low human IgG content. At the time 
Cy5-human IgG arrived, plenty of sites were still available, with little competition due to 
the high relative concentration of labeled species in the sample. Thus, due to the pre-
concentration of unlabelled species occurring during the first stage of the immunoassay, 
this assay format appeared far more sensitive to the human IgG concentration in the sample 
(Fig. 6). Taking advantage of the enhanced sensitivity at alkaline pH, the human IgG limit 
of detection of the calibration system was estimated to be around 5 µg/mL. At that pH, 
electrokinetic transport of labeled IgG could be shown to be extremely sensitive to the 
number of additional negative charges. Optimal labeling appeared to be in the range of 2 to 
3 Cy5 dyes per IgG molecule. A lower degree of labeling yielded a weaker fluorescent 
signal for the bound Cy5-human IgG at the reactive site, and reduced the assay sensitivity. 
Cy5-human IgG with a labeling degree higher than 3 was shown not to be 
electrokinetically transported to the immunochemically reactive site. 
The activity of a second batch of Cy5-human IgG (batch II) was tested by running a 
concentration dependence under alkaline assay conditions only. With four synthetic 
samples comprising analyte/tracer ratios of 0, 0.25, 0.50 and 0.75, a total of 11 chips were 
analyzed. From all data points, only one appeared to be out of the expected range. The 
internal standard value for that measurement was 9900 A.U., whereas the measured 
response for the other ten chips was > 13'000 A.U. Thus, the data of TERASYS chips 
showing an internal standard signal below 13000 A.U. were discarded. The concentration 
dependence obtained using Cy5-human IgG batch II provided a somewhat smaller 
sensitivity for human IgG compared to the results obtained with batch I (Fig. 7). 
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Fig. 7: Concentration dependence for human IgG using batch II of Cy5-human IgG 
(labelling ratio of 2.9) in comparison to batch I of Cy5-human IgG (labelling ratio of 
2.2). 
3.3 IgG monitoring in human serum 
For the determination of IgG in human serum, an assay with a calibration range between 
about 5 and 100 mg/mL is required. Using the experimental conditions that led to the data 
presented in Fig. 7 for analysis of human serum, concentration-independent data were 
obtained. Thus, the four sera obtained from the clinical chemistry laboratory of the 
Inselspital (Bern, Switzerland) with reported IgG levels of 9.2 mg/mL, 15.3 mg/mL, 35.5 
mg/mL and 64.7 mg/mL (determined using the BNII nephelometric immunoassay of Dade 
Behring) were prepared with a large excess of tracer (cf. section 2.2; analyte/tracer ratios 
of 0.0079, 0.0131, 0.0303 and 0.0553, respectively) and each sample was analyzed on four 
freshly prepared TERASYS chips. From the 16 runs, the data of 6 chips were discarded 
due to the internal standard signals being too weak. Results obtained in the properly 
working TERASYS chips showed a concentration dependence for human IgG (Fig. 8). A 
plot of the data obtained with synthetic and serum samples on the same scale (Fig. 8b) 
showed that the human IgG concentration dependence was different. With the different 
sample preparation scheme applied for serum, changes in the TERASYS responses were 
expected. Despite the 12’000-fold dilution of serum, matrix effects appear not to be 
completely abolished. No work geared towards identification of the sources of these effects 
was undertaken.  
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 8: Four patient sera were analyzed in a total of 16 TERASYS chips (4 each) using 
h II of Cy5-human IgG. (a) From all results obtained, 6 data points were discarded 
ngle; weak internal standard response). A concentration dependence for human 
 was noted for the data obtained in 10 properly working TERASYS chips (square). 
Comparison of serum sample data with those obtained for synthetic samples 
aining the Cy5-human IgG (batch II) of Fig. 7. 
t to be evaluated would be the possible interaction of serum constituents with the 
alls (e.g. adsorption of serum proteins) which could lead to the perturbation of 
okinetic delivery of analytes to the immunochemical reactive site. Quantification 
 IgG in serum was found to be difficult, due to the high RSD at a low human IgG 
tion and the small concentration dependence at higher IgG levels (Fig. 8). 
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However, the data obtained for the two patients with normal IgG levels can be clearly 
distinguished from the data of the two other patients, who had elevated IgG levels caused 
by a chronic infection (35.5 mg/mL) and cancer myeloma (64.7 mg/mL). The limit of 
detection for human IgG in serum samples was estimated at about 6 mg/mL which 
corresponds to an IgG sensitivity of 0.5 µg/mL in the 12’000-fold diluted sample. Thus, 
after elucidation of the unexplored aspects discussed above, this technology could be 
applied to the screening of patient sera with unambiguous recognition of elevated IgG 
levels. 
3.4 Reproducibility and long term stability of TERASYS IgG chips 
Clinical assays require a high level of confidence in the overall analysis process. This 
confidence in the result has been attained in the TERASYS chip thanks to the use of Cy3-
mouse IgG as internal standard. In this study, the internal standard monitoring enabled the 
selection of the chips that worked properly throughout all steps from microfabrication to 
immunoassay. In the case of patient serum analysis, 6 TERASYS chips out of 16 were not 
qualified. As seen in Fig. 8a, without such a discrimination, no concentration dependence 
behavior could have been established. Moreover, the calculation of the Cy5-to-Cy3 ratio 
(tracer-to-internal standard ratio) enhanced the assay reproducibility. Recording the 
fluorescence signal arising from Cy5 led to RSDs of about 18 % [19]. The use of the 
Cy5/Cy3 signal ratio revealed an average RSD value of 6.8 % (RSD values for the Cy5-
mouse IgG batch II data presented in Fig. 7 were determined to be between 1.8 and 13 %).  
The long-term stability of fully prepared TERASYS chips was investigated using two 
means of chip storage. In a first series of chips, PBS was left in the microfluidic network 
and the chips were stored protected from light at 4°C. A second series of chips was 
conditioned with 100-fold diluted PBS and the reservoirs were emptied. Water in the 
channels was allowed to evaporate in a vacuum chamber (0.05 mbar) and the chips were 
stored protected from light at –20°C. The purpose of that procedure was to provide salts to 
the biomolecules, which is important for stabilizing the protein structure in absence of 
water. The dilution of PBS was required to avoid channel clogging due to crystallization of 
buffer constituents. After a two-month storage period, immunoassays using a 1:1 Cy3-
mouse IgG/Cy5-human IgG solution (analyte/tracer ratio of 0) were performed under 
alkaline running conditions in both sets of chips. Ideally, data comparable to those for 0 
µg/mL human IgG obtained in freshly prepared chips (first data points in Fig. 7) would 
  
thus be obtained. Before use, dried chips were filled with PBS and rehydration of the 
biomolecules was allowed for 50 min at room temperature. Difficulties were encountered 
when PBS was introduced into the dried microchannels, mainly due to the formation of air 
bubbles. However, chips stored wet were conditioned with fresh PBS without any problem. 
Immunoassays carried out in these chips were found to perform well and reproducibly 
(Fig. 9a). The mean Cy5/Cy3 fluorescence intensity ratio was 2.07 (RSD = 8.1 %, n = 4, 
Cy5-human IgG batch II), a value that compares well with 1.94 (RSD = 6.25 %, n=3, Cy5-
human IgG batch II) obtained in freshly prepared chips. However, the performance of 
electrokinetically driven immunoassays was not possible anymore in the reconstituted, dry-
stored chips. Surface passivation did not survive the dry-storage treatment (Fig. 9b). 
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exploit a small difference between the net mobilities of analyte and tracer, thereby 
achieving a preconcentration of human IgG on the solid support that led to an increase in 
the sensitivity of the immunoassay. The overall quality of the disposable chip and the 
performance of the immunoreaction could be controlled by monitoring the fluorescence of 
the bound internal standard. Runs with abnormal internal standard responses were 
discarded. Furthermore, data evaluation was based upon calculation of the ratio between 
fluorescence intensities of bound tracer and bound internal standard (Cy5-human IgG and 
Cy3-mouse IgG, respectively), an approach that reduces the impact of chip-to-chip 
variation. Using synthetic samples, the concentration dependence in the range from 0 to 80 
µg/mL IgG was shown to provide reproducible Cy5/Cy3 signal ratios between 2 and < 0.5, 
values that vary slightly between different Cy5-human IgG batches and are associated with 
an average RSD of 6.8 %. The incorporation of the internal standard was therefore 
demonstrated to provide the level of confidence required in clinical analysis. Furthermore, 
chips wet-stored at 4 °C over a two-month period were found to perform similarly, 
whereas dried chips stored at – 20 °C and rehydrated prior to use could not be employed at 
all. The analysis of patient sera showed that the immunoassay platform behaved differently 
in presence of serum-based samples. Using the same conditions as for the synthetic 
samples, no concentration dependence was noted. With a large excess of tracer, a small 
dependence on IgG concentration was observed but did not permit exact quantification of 
IgG in these samples. Further work is required to properly elucidate the reasons leading to 
this behavior and to identify conditions yielding an increased concentration dependence. 
However, patients with normal IgG serum levels (8-16 mg/mL) could be clearly 
differentiated from patients with elevated IgG concentrations (> 16 mg/mL). Thus, these 
data show that TERASYS chips could be used for the rapid screening of patient sera. A 
more complex microchannel design containing multiple intersections with different 
immobilized specific antibodies (e.g. antibodies against IgG, kappa and lambda) could be 
developed and applied to the simultaneous on-chip monitoring of various parameters, 
including identification of a monoclonal gammopathy. This is an advantage compared to 
the use of capillary zone electrophoresis in which, after immunosubtraction with different 
antibodies applied to aliquots of serum, multiple experiments have to be performed [6]. 
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